Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04514484 · OUTCOME

12-month Progression-free Survival (PFS)

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
At 12 months (from start of treatment)

What was measured

Percentage of patients without progressive disease at 12 months.

Analysis population: Treated patients who were evaluated for efficacy.

Groups in this outcome

Treatment (Cabozantinib S-malate, Nivolumab)

Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Cabozantinib S-malate, Nivolumab)6

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Cabozantinib S-malate, Nivolumab)63Not reported1489Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        14
        upper Limit
        89
        value
        63
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Percentage of patients without progressive disease at 12 months.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
    id
    OG000
    title
    Treatment (Cabozantinib S-malate, Nivolumab)
param Type
NUMBER
population Description
Treated patients who were evaluated for efficacy.
reporting Status
POSTED
time Frame
At 12 months (from start of treatment)
title
12-month Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice